Dr. Hofmeister Discusses Checkpoint Inhibitors in Myeloma

Video

In Partnership With:

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

A trial of durvalumab (Imfinzi) and lenalidomide (Revlimid) with and without low-dose dexamethasone in patients with newly diagnosed multiple myeloma, and three other studies exploring durvalumab in multiple myeloma—MEDI4736-MM-001, MEDI4736-MM-003, and MEDI4736-MM-005—were placed on partial hold earlier in 2017.

Hofmeister hopes that with further testing they will be incorporated as relapsed, and ultimately upfront therapy for patients with multiple myeloma.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD